Cedric Menard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3452300/publications.pdf

Version: 2024-02-01

40 papers 4,590 citations

236925 25 h-index 330143 37 g-index

41 all docs

41 docs citations

times ranked

41

6826 citing authors

#	Article	IF	CITATIONS
1	Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunology, Immunotherapy, 2007, 56, 641-648.	4.2	1,104
2	CD4 + CD25 + regulatory T cells inhibit natural killer cell functions in a transforming growth factorâ€"βâ€"dependent manner. Journal of Experimental Medicine, 2005, 202, 1075-1085.	8.5	806
3	A novel dendritic cell subset involved in tumor immunosurveillance. Nature Medicine, 2006, 12, 214-219.	30.7	377
4	Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nature Medicine, 2011, 17, 700-707.	30.7	282
5	The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunological Reviews, 2006, 214, 229-238.	6.0	235
6	Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines. Journal of Immunology, 2006, 176, 2722-2729.	0.8	192
7	Clinical-Grade Mesenchymal Stromal Cells Produced Under Various Good Manufacturing Practice Processes Differ in Their Immunomodulatory Properties: Standardization of Immune Quality Controls. Stem Cells and Development, 2013, 22, 1789-1801.	2.1	186
8	Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor–Bearing Patients. Cancer Research, 2009, 69, 3563-3569.	0.9	181
9	Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunology, Immunotherapy, 2008, 57, 1579-1587.	4.2	137
10	Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood, 2012, 119, 2556-2567.	1.4	133
11	CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?. Clinical Cancer Research, 2008, 14, 5242-5249.	7.0	104
12	Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression. Journal of Clinical Investigation, 2014, 124, 5337-5351.	8.2	96
13	Comparative Study of Immune Regulatory Properties of Stem Cells Derived from Different Tissues. Stem Cells and Development, 2013, 22, 2990-3002.	2.1	89
14	Immunoregulatory properties of clinical grade mesenchymal stromal cells: evidence, uncertainties, and clinical application. Stem Cell Research and Therapy, 2013, 4, 64.	5.5	61
15	Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells. Stem Cells, 2020, 38, 146-159.	3.2	50
16	Dendritic cells and innate defense against tumor cells. Cytokine and Growth Factor Reviews, 2008, 19, 79-92.	7.2	49
17	Liposuction Preserves the Morphological Integrity of the Microvascular Network: Flow Cytometry and Confocal Microscopy Evidence in a Controlled Study. Aesthetic Surgery Journal, 2016, 36, 609-618.	1.6	49
18	The Critical Role of IL-15 in the Antitumor Effects Mediated by the Combination Therapy Imatinib and IL-2. Journal of Immunology, 2008, 180, 6477-6483.	0.8	44

#	Article	IF	CITATIONS
19	Human t(14;18)positive germinal center B cells: a new step in follicular lymphoma pathogenesis?. Blood, 2014, 123, 3462-3465.	1.4	44
20	Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab. Journal of Autoimmunity, 2015, 62, 22-30.	6.5	40
21	Brief Report: Proteasomal Indoleamine 2,3-Dioxygenase Degradation Reduces the Immunosuppressive Potential of Clinical Grade-Mesenchymal Stromal Cells Undergoing Replicative Senescence. Stem Cells, 2017, 35, 1431-1436.	3.2	40
22	Therapy-Induced Tumor Immunosurveillance Involves IFN-Producing Killer Dendritic Cells: Figure 1 Cancer Research, 2007, 67, 851-853.	0.9	33
23	Rituximab for auto-immune alveolar proteinosis, a real life cohort study. Respiratory Research, 2018, 19, 74.	3.6	32
24	Labeling of mesenchymal stromal cells with iron oxide–poly(l-lactide) nanoparticles for magnetic resonance imaging: uptake, persistence, effects on cellular function and magnetic resonance imaging properties. Cytotherapy, 2011, 13, 962-975.	0.7	30
25	Medial Thighplasty After Massive Weight Loss: Are There Any Risk Factors for Postoperative Complications?. Aesthetic Plastic Surgery, 2014, 38, 63-68.	0.9	27
26	NK cell activation and recovery of NK cell subsets in lymphoma patients after obinutuzumab and lenalidomide treatment. Oncolmmunology, 2018, 7, e1409322.	4.6	25
27	POFA trial study protocol: a multicentre, double-blind, randomised, controlled clinical trial comparing opioid-free versus opioid anaesthesia on postoperative opioid-related adverse events after major or intermediate non-cardiac surgery. BMJ Open, 2018, 8, e020873.	1.9	25
28	An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma. Blood, 2018, 132, 1486-1494.	1.4	25
29	Regulatory myeloid cells: an underexplored continent in B-cell lymphomas. Cancer Immunology, Immunotherapy, 2017, 66, 1103-1111.	4.2	19
30	Effects of a Ceramic Biomaterial on Immune Modulatory Properties and Differentiation Potential of Human Mesenchymal Stromal Cells of Different Origin. Tissue Engineering - Part A, 2015, 21, 767-781.	3.1	15
31	Stability of Cyclophosphamide and Mesna Admixtures in Polyethylene Infusion Bags. Annals of Pharmacotherapy, 2003, 37, 1789-1792.	1.9	12
32	IL-2 production by dendritic cells is not critical for the activation of cognate and innate effectors in draining lymph nodes. European Journal of Immunology, 2005, 35, 2840-2850.	2.9	12
33	Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma. Blood Advances, 2021, 5, 2063-2074.	5.2	11
34	Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. Blood, 2022, 140, 1822-1826.	1.4	8
35	Follicular Lymphoma-Like B Cells In Healthy Individuals Are Released From Pretumoral Niches Established In Secondary Lymphoid Tissues. Blood, 2010, 116, 466-466.	1.4	4
36	Iterative Germinal Center Re-Entries of Memory B-Cells with $t(14;18)$ Translocation and Early Steps of Follicular Lymphoma Progression. Blood, 2012, 120, 150-150.	1.4	3

#	Article	IF	CITATIONS
37	Mechanically Isolated Stromal Vascular Fraction Provides a Valid and Useful Collagenase-Free Alternative Technique: A Comparative Study. Plastic and Reconstructive Surgery, 2017, 139, 572e-573e.	1.4	O
38	Effects Of a Novel Ceramic Biomaterial On Immune Modulatory Properties and Differentiation Potential Of Mesenchymal Stromal Cells. Blood, 2013, 122, 4858-4858.	1.4	0
39	Quality Controls Of Immune Regulatory Properties Of Ex-Vivo, GMP-Grade Expanded Mesenchymal Stromal Cells For Clinical Use. Blood, 2013, 122, 5413-5413.	1.4	O
40	Immune Regulatory Properties Are a Common Feature Of Stem Cells. Blood, 2013, 122, 5419-5419.	1.4	0